-
Product Insights
New![]()
Cardiff Waste to Energy Facility
Cardiff Waste to Energy Facility is a biopower project located in Wales, United Kingdom. The project is owned by Valencia Waste Management Ltd. The project came online in 2015. Empower your strategies with our Cardiff Waste to Energy Facility report and make more profitable business decisions. Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 to 3 business day of the purchase, excluding weekends and holidays. Certain sections of the...
-
Product Insights
New![]()
Net Present Value Model: Cardiff Oncology Inc’s Onvansertib Fumarate
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Net Present Value Model: Neurocrine Biosciences Inc’s NBI-921352
Determining the value of drugs is a complicated practice and requires a deep knowledge of the drug itself, the current market, and knowledge of expected cash inflows, outflows, and potential success rates for each stage of drug development. GlobalData has done all of this work for you, Drugs Intelligence database to create high-value, risk-adjusted NPV models.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Amifampridine Phosphate La in Lambert–Eaton Myasthenic Syndrome (LEMS)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Amifampridine Phosphate La in Lambert–Eaton Myasthenic Syndrome (LEMS)Drug Details: Amifampridine phosphate is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – TK-001 in Breast Cancer
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TK-001 in Breast Cancer Drug Details: TK-001 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Nemtabrutinib in Diffuse Large B-Cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Nemtabrutinib in Diffuse Large B-Cell Lymphoma Drug Details: Nemtabrutinib (ARQ-531) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Maplirpacept in Follicular Lymphoma
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.Maplirpacept in Follicular LymphomaDrug Details:Maplirpacept (TTI-622) is under development for the treatment of relapsed and refractory...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Deuterated etifoxine in Generalized Anxiety Disorder (GAD)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Deuterated etifoxine in Generalized Anxiety Disorder (GAD) Drug Details: Deuterated etifoxine is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Small-Cell Lung Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Onvansertib Fumarate in Small-Cell Lung Cancer Drug Details:Onvansertib fumarate (PCM-075) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Triple-Negative Breast Cancer (TNBC)
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Onvansertib Fumarate in Triple-Negative Breast Cancer (TNBC) Drug Details:Onvansertib fumarate (PCM-075) is under development for the...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Colorectal Cancer
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Onvansertib Fumarate in Colorectal Cancer Drug Details:Onvansertib fumarate (PCM-075) is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Pancreatic Ductal Adenocarcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Onvansertib Fumarate in Pancreatic Ductal Adenocarcinoma Drug Details: Onvansertib fumarate (PCM-075) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Refractory Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Onvansertib Fumarate in Refractory Acute Myeloid Leukemia Drug Details: Onvansertib fumarate (PCM-075) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Relapsed Acute Myeloid Leukemia
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Onvansertib Fumarate in Relapsed Acute Myeloid Leukemia Drug Details: Onvansertib fumarate (PCM-075) is under development...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Metastatic Colorectal Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Onvansertib Fumarate in Metastatic Colorectal Cancer Drug Details: Onvansertib fumarate (PCM-075) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Onvansertib Fumarate in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Onvansertib Fumarate in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) Drug Details: Onvansertib fumarate (PCM-075)...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Iparomlimab + Tuvonralimab in Small-Cell Lung Cancer
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Iparomlimab + Tuvonralimab in Small-Cell Lung Cancer Drug Details: Tuvonralimab (PSB-205) in combination with iparomlimab is under development...
-
Product Insights
![]()
East Bay Cardiff – Opto Student Cardiff – Cardiff
Equip yourself with the essential tools needed to make informed and profitable decisions with our East Bay Cardiff - Opto Student Cardiff - Cardiff report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep into...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Baricitinib in Systemic Idiopathic Juvenile Arthritis
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Baricitinib in Systemic Idiopathic Juvenile Arthritis Drug Details:Baricitinib (Olumiant) is an anti-inflammatory, immunomodulating and antineoplastic agent....
-
Product Insights
![]()
Cardiff Athletic Club – Cardiff Arms Park Stadium Redevelopment – Cardiff
Equip yourself with the essential tools needed to make informed and profitable decisions with our Cardiff Athletic Club - Cardiff Arms Park Stadium Redevelopment - Cardiff report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.